| Literature DB >> 34107340 |
Sarah A Holstein1, Nizar Bahlis2, P Leif Bergsagel3, Manisha Bhutani4, Niccolo Bolli5, Carrie Brownstein6, Pierre Demolis7, David Foureau4, Francesca Gay8, Irene M Ghobrial9, Nicole Gormley10, Jens Hillengass11, Martin Kaiser12, Marcela V Maus13, J Joseph Melenhorst14, Maximilian Merz15, Michael O Dwyer16, Bruno Paiva17, Marcelo C Pasquini18, Nina Shah19, Sandy W Wong19, Saad Z Usmani4, Philip L McCarthy11.
Abstract
The fifth annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma was conducted as one of the American Society of Hematology Annual Meeting Scientific Workshops on Thursday December 3, 2020. This workshop focused on four main topics: (1) integrating minimal residual disease into clinical trial design and practice; (2) the molecular and immunobiology of disease evolution and progression in myeloma; (3) adaptation of next-generation sequencing, next-generation flow cytometry, and cytometry by time of flight techniques; and (4) chimeric antigen receptor T-cell and other cellular therapies for myeloma. In this report, we provide a summary of the workshop presentations and discuss future directions in the field.Entities:
Keywords: CAR T-cell; Cellular therapy; Endpoint; Immune profiling; Minimal residual disease; Multiple myeloma
Mesh：
Substances：
Year: 2021 PMID： 34107340 PMCID： PMC8478786 DOI： 10.1016/j.jtct.2021.05.027
Source DB: PubMed Journal: Transplant Cell Ther ISSN： 2666-6367